Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Alpha radiation emitter

DRUG CLASS:

Alpha radiation emitter

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

TMPRSS2-ERG fusion	Prostate Cancer	TMPRSS2-ERG fusion	Prostate Cancer	radium Ra-223 dichloride Resistant: C2 – Inclusion Criteria radium Ra-223 dichloride Resistant : C2	radium Ra-223 dichloride Resistant: C2 – Inclusion Criteria radium Ra-223 dichloride Resistant : C2
SSTR Expression	Neuroendocrine Tumor	SSTR Expression	Neuroendocrine Tumor	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3
RB deletion	Prostate Cancer	RB deletion	Prostate Cancer	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
CD33 expression	Acute Myelogenous Leukemia	CD33 expression	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	I-131-apamistamab Sensitive: C3 – Early Trials I-131-apamistamab Sensitive : C3	I-131-apamistamab Sensitive: C3 – Early Trials I-131-apamistamab Sensitive : C3
ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
SSTR2 overexpression	Small Cell Lung Cancer	SSTR2 overexpression	Small Cell Lung Cancer	RYZ101 Sensitive: D – Preclinical RYZ101 Sensitive : D	RYZ101 Sensitive: D – Preclinical RYZ101 Sensitive : D
EGFRvIII expression	Glioblastoma	EGFRvIII expression	Glioblastoma	Undisclosed EGFRvIII-targeted alpha therapy Sensitive: D – Preclinical Undisclosed EGFRvIII-targeted alpha therapy Sensitive : D	Undisclosed EGFRvIII-targeted alpha therapy Sensitive: D – Preclinical Undisclosed EGFRvIII-targeted alpha therapy Sensitive : D
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	BAY2701439 Sensitive: D – Preclinical BAY2701439 Sensitive : D	BAY2701439 Sensitive: D – Preclinical BAY2701439 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: D – Preclinical lintuzumab-Ac225 Sensitive : D	lintuzumab-Ac225 Sensitive: D – Preclinical lintuzumab-Ac225 Sensitive : D